What's new

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Feb 12, 2025 - 16:46
 0
Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised
Read More

Tags:

Previous Article

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

Next Article

FERC approves PJM’s fast-track power plant interconnection plan

Related Posts

Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Date of authorisation: 13/03/2001, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): mResvia, Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Nimenrix, meningococcal groups A, C, W-135 and Y conjugate vaccine, Date of authorisation: 20/04/2012, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0